Forte Biosciences Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
5analysts covering
FY EPS (est.)
-$3.93next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 14 Nov 2026 |
| Full Year 2026 Earnings Release | 23 Mar 2027 |
Monitoring Framework
Key Performance Indicators
FB102 Phase 2 Celiac Disease Topline Readout QuarterlyTarget: Positive efficacy and safety data replicating Phase 1b VCIEL histologic endpoint (p=0.0099)
FB102 Phase 1b Vitiligo Topline Readout QuarterlyTarget: Positive proof-of-concept data demonstrating clinical efficacy in non-segmental vitiligo
FB102 Phase 1b Alopecia Areata Topline Readout QuarterlyTarget: Positive proof-of-concept data demonstrating clinical efficacy in alopecia areata
Cash Runway Quarterly58.2MTarget: Sufficient capital to fund operations through multiple Phase 2 readouts
Watch Items
- FB102 Phase 2 Celiac Disease Trial Topline DataTrigger: Topline data release expected in 2026Action: Evaluate histological and symptom-based efficacy endpoints against placebo to determine Phase 3 viability.
- FB102 Phase 1b Vitiligo Trial Topline DataTrigger: Topline data release expected in 1H 2026 / shortlyAction: Assess safety and efficacy signals to determine if the program warrants advancement into Phase 2.
- FB102 Phase 1b Alopecia Areata Trial Topline DataTrigger: Topline data release expected in 2026Action: Analyze clinical efficacy and safety profile to determine next development steps.
- Cash Burn Rate and Financial RunwayTrigger: Quarterly cash burn exceeding $25 millionAction: Re-evaluate clinical trial prioritization and timeline expectations to preserve capital.
Research as of 20 Jun 2026